Sunday, October 13, 2024 from 2:15 PM to 3:45 PM MST at Convention Center North Building / Meeting Room 122
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-24-126-L01-PActivity Type: An Application-Based ActivityHepatorenal syndrome (HRS) is a serious complication of advanced liver disease, characterized by kidney dysfunction related to circulatory changes caused by cirrhosis and associated with significant mortality. Although HRS is considered a diagnosis of exclusion, the diagnostic criteria for HRS have recently been revised to reflect differences in AKI in patients with cirrhosis. Additionally, although treatment options are limited for the treatment of HRS, terlipressin has been recently approved for use in the United States for this indication. The purpose of this session is to provide updates in the diagnostic criteria for HRS and management of HRS including vasoactive therapy and use of albumin.
Learning Objectives1. Describe the pathophysiology of decompensated cirrhosis and hepatorenal syndrome.
2. Apply the updated diagnostic criteria for HRS-AKI to patient cases.
3. Distinguish between vasoconstrictor therapies for the treatment of HRS-AKI.
4. Evaluate appropriate patient candidacy for vasoconstrictor therapies based on risk of adverse effects.
5. Compare the various fluid strategies studied for the treatment of HRS-AKI.
6. Recommend an albumin regimen for a patient treated for HRS-AKI.
 | Moderator: | Stephanie Bass, Pharm.D., FCCP, BCPS | | Medical ICU Clinical Pharmacist
Cleveland Clinic
Cleveland, Ohio | View Biography |
|